The central role of Wnt/beta catenin signaling in CML LSC proliferation and persistence under TK inhibitor therapy suggests a differentiation-dependent regulation of its antagonists, including Cby1 [5], [7]. The gene discussed is CTNNB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.